- Email: [email protected]
Subject Index to Volume 63
SUBJECT INDEX TO VOLUME 63 ACN9, 1047 Acquired immunodeficiency syndrome, 899 Acyl ghrelin, 245 Addiction brain norepinephrine and, 1005 orbitofrontal cortex and, 256 Adenylyl cyclase 1, 1013 Adenylyl cyclase 8, 1013 Adolescents alcoholism in, 146 anxiety disorders in, functional magnetic resonance imaging of, 563 conduct disorder in, 279 emotional reactivity in, 927 right prefrontal cortical folding in, with schizophrenia risk, 80 schizophrenia in clozapine and olanzapine for, 524 event-related potentials in, 784 right prefrontal cortical folding in at-risk adolescents, 80 -Adrenergic receptors, 1007 Affective disorder personality risk factors for, frontolimbic serotonin 2A receptor binding in, 569 Affiliative behaviors in autism spectrum disorder, 911 genes controlling, 911 prolactin and, 909 studies of, 909 Aggression model of, 271 social, testosterone and, 263 territorial, 271 AKT1, 449 Alcohol dependence ACN9 and, 1047 Alcohol use CHRNA5/A3/B4 genes and, 1039 Alcoholism in adolescents, 146 corticotropin-releasing factor and, 137, 139 Crhr1 and, 139, 146 Allodynia, 633 Alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors. See AMPA receptors Alzheimer’s disease subjective memory complaints, 609 AMPA receptors, 347, 349 Amygdala in chronic corticosteroid patients, 704 in familial early onset major depressive disorder, 385 fear learning, rostral anterior cingulate cortex modulation of, 821 rostral anterior cingulate cortex and, 858 serotonin transporter genotype and, 852 Anorexia nervosa acyl ghrelin for, 245 des-acyl ghrelin for, 245 obestatin for, 245 Anterior cingulate cortex attention-deficit/hyperactivity disorder and, 332 gray matter loss, in post-traumatic stress disorder, 550 methamphetamine effects on, 184 0006-3223/08/$34.00 doi: 10.1016/S0006-3223(08)00576-3
precuneus and, 332 rostral amygdala and, 858 amygdala-dependent fear learning modulated by, 821 depressed mood and, 391 vesicular glutamate transporter expression alterations in, in schizophrenia, 766 Anterior cingulotomy major depression treated with, 670 Anterior limb of interior capsule schizophrenia-related reductions in, 65 Antidepressants brain-derived neurotrophic factor and, 640, 642 ERK MAP kinase, 353 intracellular factors, 353 ketamine effects, 347, 348 methylphenidate-induced behavioral deficits normalized with, 309 neuropathic allodynia treated with, 633 Antipsychotic drugs astrocytes affected by, 759 oligodendrocytes affected by, 759 RGS4 variants effects on, for schizophrenia, 32 Anxiety/anxiety disorders in adolescents, functional magnetic resonance imaging of, 563 cocaine-induced, norepinephrine signaling through adrenergic receptors and, 1007 community versus clinical sampling, 884 family aggregation of, 884 serotonin transporter gene polymorphisms and, 840 Apolipoprotein E E4 allele, 609 Apomorphine gating-disruptive effects of, 748 Approach-related personality traits dopamine D4 receptor and, 197 Astrocytes, 759 Attachment infant, maternal love effects on, 415 Attentional engagement prefrontal inhibitory control deficits in schizophrenia associated with reductions in, 776 Attention-deficit/hyperactivity disorder blood lead levels and, 325 cingulate-precuneus interactions and, 332 emotional expressions in, misinterpreting of, 917 event-related potentials in, 784 methylphenidate for, 981 neurotrophic factors associated with genetic susceptibility to, 935 prolonged-release methylphenidate for, 981 Autism spectrum disorder affiliative behaviors and, 911 chromosomal abnormalities in, 1111 cognitive set in, 974 executive function in, 974 neural circuitry mediating shifts in behavioral response, 974 Behavior methylphenidate-induced deficits, antidepressants for normalization of, 309 self-injurious, 990 BIOL PSYCHIATRY 2008;63:1215–1221 © 2008 Society of Biological Psychiatry
1216 BIOL PSYCHIATRY 2008;63:1215–1221 Behavioral activation system dysregulation theory of bipolar disorder, 692 Biogenesis of lysosome-related organelles complex 1, 24 Bipolar disorder behavioral activation system dysregulation theory of, 692 biopsychosocial model of, 692 D-serine metabolism and, 997 left frontal cortical responses affected by, 692 mood symptoms in lamotrigine effects on, 125 pericentrin 2 expression in, 678 rapid cycling, 125 Brain cocaine responses, expectation effects on, 222 in schizophrenia loss of volume, 107 morphology, 475 structure patterns, 118 Brain rhythms, in schizophrenia, 728 Brain-derived neurotrophic factor antidepressant response and, 640, 642 in dentate gyrus, 642 hippocampal, 642 loss of, in dentate gyrus, 642 obsessive-compulsive disorder, 619 Bupropion nicotine patch and, for smoking cessation in schizophrenia, 1092 Cannabinoid-1 receptors, 1075 Catechol-O-methyltransferase working memory in schizophrenia affected by genetic variations in, 72 Caudate nucleus hyperactivity, in obsessive-compulsive disorder, 558 CB1 receptor, 1030 Cerebrum anomalous asymmetry of, in schizophrenia patients, 793 loss of volume, in schizophrenia, 107 Children alcohol use, 1039 depression in, 391 parental loss, effect on adult hypothalamic-pituitary-adrenal axis, 1147 tobacco use, 1039 CHRNA5/A3/B4 genes, 1039 Chromosomes, 7, 13, 594, 1047 abnormalities in, in autism spectrum disorder, 1111 15q25-26 linkage region, 1185 Cingulotomy, anterior major depression treated with, 670 Clozapine, 524 Cocaine anxiety induced by, norepinephrine signaling through adrenergic receptors and, 1007 expectation effects on brain responses to, 222 prenatal exposure to, 214, 1066 rewarding potency of, prenatal exposure effects on, 214 serotonin-6 receptors and, 207 Cocaine- and amphetamine-regulated transcript, 152 Cognitive control attention-deficit/hyperactivity disorder and, 325 Cognitive deficits in schizophrenia www.sobp.org/journal
Subject Index to Volume 63 ␣7 nicotinic receptor agonists for, 92 SSR180711 for, 92 Cognitive dysfunction psychotic disorders and, 602 Cognitive function magnetic seizure therapy and electroconvulsive shock effects on, 1163 Cognitive-behavioral therapy D-cycloserine enhancement of, for social anxiety, 544 Compulsivity orbitofrontal cortex damage and, 253 Conduct disorder in adolescents, 279 fear conditioning and affective modulation of startle reflex in, 279 Corticosteroids chronic use, amygdala volume in patients receiving, 704 Corticotropin-releasing factor alcoholism and, 137, 139 prepulse inhibition deficits mediated by, 360 raphe efferent activation to medial prefrontal cortex by, 832 CREB binding and activity of, 710 electroconsulvive seizures and, 710 Crhr1 alcoholism and, 139, 146 Cyclic adenosine monophosphate response element binding protein. See CREB Cytokines in schizophrenia, 801 D1, 1066 D-cycloserine cognitive-behavioral therapy for social anxiety enhanced using, 544 fear extinction and exposure therapy facilitated using, 1118 Decision making by stimulant users, 1054 Deep brain stimulation in obsessive-compulsive disorder, 542 Delta-opioid receptors, 633 Dentate gyrus brain-derived neurotrophic factor loss in, 642 pERK1/2 in, 353 Depression in children, 391 in elderly, white matter lesions as predictor of, 663 familial, 406 FKBP5 gene in, 1103 neurobiological markers of, 656 pharmacogenetic studies of, 1101 rostral anterior cingulate cortex volume and, in children, 391 selective serotonin reuptake inhibitor-resistant, 699 serotonin transporter gene polymorphisms and, 840, 847 white matter lesions and, in elderly, 663 Des-acyl ghrelin, 245 Dexamethasone/corticotropin-releasing factor test in men with major depression, 398 Diffusion tensor imaging of schizophrenia superior longitudinal fasciculus and working memory in, 512 white matter in, 519
Subject Index to Volume 63 Dizocilpine behaviors induced by, N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors for reduction of, 86 DKK4 schizophrenia and, 13 Dopamine D4 receptor approach-related personality traits and, 197 C-521T variant, 197 Dopamine D2 receptors in striatum, [18F]fallypride positron emission tomography evaluation of, 241 Dopaminergic agents prenatal cocaine exposure effects on, 214 Dorsal raphe nucleus, 1135 Dorsolateral prefrontal cortex imbalances in, in major depression, 369 Drug addiction brain norepinephrine and, 1005 orbitofrontal cortex and, 256 Drug-seeking behavior cocaine- and amphetamine-regulated transcript expression in, 152 hypothalamic neuropeptide systems and, 152 N-Acetylcysteine effects on, 338 orexin expression, 152 D-serine, 997 DTNBP1 methamphetamine psychosis associated with, 191 Dysbindin schizophrenia and, 24, 484 Elderly, depression in white matter lesions as predictor of, 663 Electroconsulvive seizures CREB and, 710 Electroconvulsive shock, 1163 Electroencephalographic alpha measures response to selective serotonin reuptake inhibitors predicted by, 1171 Emotion hippocampal lesions’ effect on, 1084 neural bases of regulation of, 577 Emotional expressions in attention-deficit/hyperactivity disorder, 917 Emotional interference processing in affective and cognitive-control brain circuitry in major depression, 377 Emotional judgment, 369 Emotional reactivity in adolescence, 927 Endocannabinoid system description of, 286 3,4-methylenedioxymethamphetamine response and, 1030 ERK MAP kinase, 353 Error processing by stimulant users, 1054 Event-related potentials in adolescents with schizophrenia, 785 in attention-deficit/hyperactivity disorder, 784 P3(00), 864 Executive function in autism, 974 Expectation, cocaine, 222
BIOL PSYCHIATRY 2008;63:1215–1221 1217 Extinction N-Acetylcysteine effects on, in cue- and heroin-induced drug seeking, 338 Face processing impairments in, in 22q11.2 deletion syndrome, 49 Familial depression, 406 Fear conditioning affective modulation of startle reflex and, in early-onset conduct disorder, 279 self-report fears and, genetic covariation between, 587 stress and, 819 Fear extinction and exposure therapy, 1118 Fear learning, amygdala-dependent, 821 Fetal alcohol exposure limbic-hypothalamic-pituitary-adrenal axis regulation affected by, 317 neonatal irritability and, 317 Fibroblast growth factors, 953 FKBP5, 1103 Fluoxetine, 1135 Fragile X syndrome, 963 Frontolimbic serotonin 2A receptor binding in affective disorder, 569 Frontotemporal lobe degeneration complex diseases, 946 Functional magnetic resonance imaging of adolescents with anxiety disorders, 563 face processing impairments in 22q11.2 deletion syndrome revealed with, 49 GABA transmission, 963 Gamma oscillations in neocortex, ketamine and MK-801 effects on, 730 in schizophrenia, 744 sensory-evoked, in chronic schizophrenia, 744 Gaze oxytocin effects on, 3 Generalized anxiety disorder riluzole for, hippocampal N-acetylaspartate concentration correlated with response to, 891 venlafaxine for, 858 Genome-wide association studies, 439 Glucocorticoid receptors, 360 Glutamate proton magnetic resonance spectroscopy measurement of, in premenstrual dysphoric disorder, 1178 release of in anterior cingulate cortex of schizophrenia patients, 766 ketamine effects on, 349 Gray matter loss in post-traumatic stress disorder, 550 in schizophrenia, 107 Heart rate, 1141 Heroin dependence hypothalamic-pituitary-adrenal axis response in, 172 metyrapone response in patients with, 172 N-acetylcysteine effects on seeking of, 338 Herpes simplex virus maternal exposure to, psychosis risks among offspring secondary to, 809 www.sobp.org/journal
1218 BIOL PSYCHIATRY 2008;63:1215–1221 Hippocampus in familial early onset major depressive disorder, 385 lesions in, emotional responses disrupted by, 1084 N-acetylaspartate concentration in, riluzole response for generalized anxiety disorder correlated with, 891 5-HT7 receptor phencyclidine-induced prepulse inhibition affected by inactivation of, 98 Human immunodeficiency virus, 899 Hypothalamic-pituitary-adrenal axis adult, childhood parental loss effects, 1147 childhood trauma effects on, 398, 1147 reactivity of, 847 regulation of, fetal alcohol exposure effects on, 317 stress-associated dysregulation of, 539 Impulse control nicotine seeking and, 301 Impulsivity nicotine seeking and, 301 orbitofrontal cortex damage and, 253 Infant maternal love effects on attachment behaviors in, 415 Inflammation, 1022 Inflammatory cytokines in schizophrenia, 801 Interior capsule anterior limb of, in schizophrenia, 65 Interneurons inhibitory cortical, deficiency in, 953 in neocortex, 650 -opioid receptor, 286 Ketamine antidepressant effects, 347, 349 glutamate release affected by, 349 locomotor sensitization to chronic use of, 178 wake-related aberrant ␥ oscillations in neocortex induced by, 730 Lamotrigine bipolar disorder-related mood symptoms treated with, 125 Lead exposure attention-deficit/hyperactivity disorder and, 325 Limbic system deactivation of, during acute psychosocial stress, 234 Linkage-disequilibrium mapping, 1185 Locomotor behavior sensitization of, to chronic ketamine use, 178 Loss-chasing, 293 Magnetic seizure therapy, 1163 Major depression amygdala volumes in, 385 anterior cingulotomy for, 670 chromosome 15q25-26 linkage region, 1185 dexamethasone/corticotropin-releasing factor test in, 398 dorsolateral prefrontal cortex imbalances in, 369 emotional interference processing alterations in, 377 familial, 385 hippocampal volumes in, 385 incentives in, 686 memory sensitivity for negative stimuli in, 1155 www.sobp.org/journal
Subject Index to Volume 63 monetary incentives in, neural responses to, 686 negativity bias in, 377 neuroticism and, 569 triiodothyronine augmentation in, brain bioenergetics and response to, 1127 Maternal love functional neuroanatomy of, 415 MDMA. See 3,4-Methylenedioxymethamphetamine Medical research, 725 MEGF10, 441 Memory sensitivity for negative stimuli in major depression, 1155 subjective, 609 Metabotropic glutamate receptors N-acetylaspartylglutamate peptidase inhibition via, for phencyclidine and dizocilpine induced behaviors, 86 Methamphetamine anterior cingulate cortex affected by, 184 psychosis induced by, DTNBP1 associated with, 191 response inhibition impairments caused by, 184 Methylation of reelin promoter region in schizophrenia, 530 3,4-Methylenedioxymethamphetamine, 1030 Methylenetetrahydrofolate reductase polymorphisms negative symptoms in schizophrenia correlated with, 42 ␣-Methyl-para-tyrosine, 241 Methylphenidate behavioral deficits induced by, antidepressant treatment effects, 309 emotional expressions in attention-deficit/hyperactivity disorder affected by, 917 prolonged-release, 981 Metyrapone mood and neuroendocrine response to, in heroindependent patients, 172 Mismatch negativity in schizophrenia, 58 MK-801 wake-related aberrant ␥ oscillations in neocortex induced by, 730 Monetary incentives in major depression, 686 Monoamine oxidase inhibitors nicotine withdrawal-induced place aversion prolonged by, 159 Motor cortex repetitive transcranial magnetic stimulation-induced inhibition of, 231 N-acetylaspartate, 891 N-acetylaspartylglutamate peptidase inhibition phencyclidine and dizocilpine induced behaviors reduced by, 86 N-Acetylcysteine heroin-induced drug seeking reduced by, 338 Natural killer cells, 899 Negative emotion, 577 Negative emotional judgment, 369 Neocortex interneurons in, 650 ketamine and MK-801 inducement of wake-related aberrant ␥ oscillations in, 730 Neuregulin 1 gene missense mutations on, 17 schizophrenia and, 17
Subject Index to Volume 63 Neurokinin 1 receptor territorial aggression and, 271 Neuronal oscillation, 1075 Neuropathic allodynia, 633 Neuroticism human-mouse quantitative trait locus concordance and, 874 major depression and, 569 Neurotrophic factors genetic susceptibility to attention-deficit/hyperactivity disorder and, 935 Nicotine. See also Tobacco smoking craving, 164 impulse control and, 301 impulsivity and, 301 non-drug-related rewards and, 1061 withdrawal-induced place aversion, monoamine oxidase inhibition effects on, 159 Nicotine patch bupropion and, for smoking cessation in schizophrenia, 1092 ␣7 Nicotinic receptor agonists cognitive deficits in schizophrenia treated with, 92 NMDA schizophrenia and, 9 NMDA antagonists ketamine. See Ketamine MK-801, 730 wake-related aberrant ␥ oscillations in neocortex induced by, 730 Norepinephrine drug addiction and, 1005 signaling through -adrenergic receptors, cocaine-induced anxiety secondary to, 1007 NTRK2, 619 NTRK3, 1185 Nucleus accumbens gene expression in, 748 serotonin-6 receptor expression in, effects on cocaine addiction, 207 signaling pathways, 748 Obestatin, 245 Obsessive-compulsive disorder BDNF/NTRK2 signaling pathway in genetic susceptibility to, 619 caudate nucleus hyperactivity in, 558 deep brain stimulation in, 542 neuronal single-unit recordings in, 542 obsessions in, 558 Olanzapine, 524 Oligodendrocytes, 759 Opiate dependence, 1013 Orbitofrontal cortex damage to, impulsivity and compulsivity and, 253 drug addiction and, 256 Orexin drug-seeking behavior and, 152 Oxytocin gaze affected by, 3 peer recognition and, 3 P3(00) event-related potential, 864 Panic disorder
BIOL PSYCHIATRY 2008;63:1215–1221 1219 chromosome 13 and, 594 Pathological gambling loss-chasing in, 293 Pergolide repetitive transcranial magnetic stimulation potentiated by, 231 Pericentrin 2 expression of, in bipolar disorder, 678 Peripheral inflammation, 1022 pERK1/2, 353 Phencyclidine behaviors induced by, N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors for reduction of, 86 cognitive deficits induced by, SSR180711 for, 92 prepulse inhibition disruption induced by, 5-HT7 receptor inactivation effects on, 98 Phenomics, 439 PICK1, 997 Place aversion, nicotine withdrawal-induced, 159 Positron emission tomography [18F], 241 limbic system deactivation during acute psychosocial stress evaluated using, 234 Post-traumatic stress disorder anterior cingulate gray matter loss in, 550 cortical reduction from, 539 prazosin effects on nighttime symptoms in, 629 twin study of, 539 Prazosin, 629 Precuneus anterior cingulate cortex and, in attention-deficit/ hyperactivity disorder, 332 Prefrontal cortex dorsolateral, imbalances in major depression, 369 medial, raphe efferent activation by corticotropin-releasing factor, 832 in nonpsychotic siblings of schizophrenia individuals, 490 right prefrontal cortical folding in adolescents at risk for schizophrenia, 80 Pregnancy herpes simplex virus exposure, psychosis risks among offspring secondary to, 809 Premenstrual dysphoric disorder, 1178 Prenatal period cocaine exposure during, 214, 1066 Prepulse inhibition apomorphine sensitivity, 748 CRF1 mediation of deficits in, 360 neuregulin 1 gene missense mutations effect on, 17 phencyclidine-induced, 5-HT7 receptor inactivation effects on, 98 Progranulin gene, 946 Prolactin, 909 Proton magnetic resonance spectroscopy of glutamate levels in premenstrual dysphoric disorder, 1178 Psychomotor slowing, 1022 Psychosis maternal exposure to herpes simplex virus associated with psychosis in offspring, 809 methamphetamine-related, DTNBP1 associated with, 191 Psychosocial stress limbic system deactivation during, 234 www.sobp.org/journal
1220 BIOL PSYCHIATRY 2008;63:1215–1221 Psychotic disorders cognitive dysfunction and, 602 Quantitative trait locus human-mouse concordance, 874 for P3 amplitude, 864 22q11.2 deletion syndrome face processing impairments in, 49 Raphe efferents, 832 Raphe nucleus, 1135 Recognition memory, delayed in schizophrenia, 498 Reelin promoter region in schizophrenia, 530 Relocation stress, 990 Repetitive transcranial magnetic stimulation dopaminergic potentiation of motor cortex inhibition induced by, 231 Response inhibition methamphetamine effects on, 184 RGS4 schizophrenia response to antipsychotic treatment affected by, 32 Ribonucleic acid, 946 Right prefrontal cortical folding in adolescents at risk for schizophrenia, 80 Riluzole, 891 Rostral anterior cingulate cortex amygdala-dependent fear learning modulated by, 821 depression in children correlated with volume of, 391 Sad facial processing, 656 Salvinorin A, 286 Sarcosine, 9 Schizophrenia adolescents clozapine and olanzapine for, 524 event-related potentials in, 784 right prefrontal cortical folding in at-risk adolescents, 80 AKT1 and, 449 anterior cingulate cortex, 766 antipsychotic treatment for RGS4 variants associated with response to, 32 biogenesis of lysosome-related organelles complex 1 protein involvement in, 24 brain rhythms in, 728 brain structure patterns in, 118 brain volume in, 107, 475 bupropion and nicotine patch for smoking cessation in, 1092 cannabinoid-1 receptors effects on sensory gating and neuronal oscillation, 1075 cognitive deficits in, ␣7 nicotinic receptor agonists for, 92 cytokine alterations in, 801 delayed recognition memory in, 498 DKK4 and, 13 D-serine metabolism and, 997 dysbindin and, 24, 484 early-onset clozapine for, 524 mismatch negativity patterns in, 58 www.sobp.org/journal
Subject Index to Volume 63 olanzapine for, 524 white matter in, 519 endophenotype, 458, 498 first-degree relatives of patients with, striatal dopamine synthesis in, 114 forward model circuitry dysfunction in, 736 functional deficits in, 505 gamma oscillations in, sensory-evoked, 744 gray matter volume and, 465 inflammatory cytokine alterations in, 801 interior capsule anterior limb in, 65 late, mismatch negativity patterns in, 58 MEGF10 and, 441 methylenetetrahydrofolate reductase polymorphisms and, 42 mismatch negativity reduction patterns in, 58 motor-sensory communication dysfunction in, 736 negative symptoms in, 42, 86 neuregulin 1 gene and, 17 neuropsychological deficits in, 505 NMDA and, 9 nonverbal delayed recognition in, 498 phenotypes for, 458, 465 predictors of, 80 prefrontal cortex function in, 490 prefrontal inhibitory control deficits in, attentional engagement effects on, 776 progressive brain volume loss in, 107 reelin promoter region in, methylation status of, 530 sarcosine for, 9 smoking cessation in, 1092 striatal dopamine synthesis in first-degree relatives of patients with, 114 superior longitudinal fasciculus in, 512 vesicular glutamate transporter expression alterations in, 766 visual processing deficits in, 484 voxel-based morphometry analyses in, 465, 793 white matter in, 519 wnt signaling genes in, 13 working memory in catechol-O-methyltransferase genetic variation effects on, 72 diffusion tensor imaging of, 512 Seizures, electroconsulvive CREB and, 710 Selective serotonin reuptake inhibitors depression resistant to, 699 electroencephalographic alpha measures predict therapeutic response to, 1171 natural killer cell innate immunity affected by, 899 venlafaxine and, comparison between, 424 Self-injurious behavior, 990 Sensory gating, 1075 Serotonin 2A receptor binding in affective disorder, 569 Serotonin 1A receptors, 1135 Serotonin-6 receptors cocaine addiction and, 207 Serotonin transporter gene polymorphisms amygdala activation and, 852 anxiety disorders and, 840 depression and, 840, 847
BIOL PSYCHIATRY 2008;63:1215–1221 1221
Subject Index to Volume 63 limbic-hypothalamic-pituitary-adrenal axis regulation and, 317 neonatal irritability and, 317 stress and, 847 Smoking. See also Nicotine bupropion and nicotine patch for cessation of, in schizophrenia, 1092 CHRNA5/A3/B4 genes and, 1039 reward responsiveness and, 1061 Social aggression testosterone effects, 263 Social anxiety chromosome 13 and, 594 D-cycloserine enhancement of exposure therapy for, 544 SSR180711, 92 Startle reflex affective modulation of, in early-onset conduct disorder, 279 Stimulants behavioral and neural activation responses to error rates during decision making in users of, 1054 Stress fear conditioning and, 819 low heart rate as marker of resilience to, 1141 nicotine craving induced by, 164 psychosocial, limbic system deactivation during, 234 sensitivity to, 164 serotonin transporter gene and, 847 Striatum D1 signaling in, 1066 dopamine synthesis, in first-degree relatives of schizophrenia patients, 114 GABA transmission, in mouse model for fragile X syndrome, 963 immediate-early gene induction in, after prenatal cocaine exposure, 1066
Subjective memory complaints, 609 Substantia nigra, 1022 Superior longitudinal fasciculus in schizophrenia, 512 Territorial aggression neurokinin 1 receptor blockade and, 271 Terrorism, 725 Testosterone social aggression and, 263 Tobacco smoking. See also Nicotine bupropion and nicotine patch for cessation of, in schizophrenia, 1092 CHRNA5/A3/B4 genes and, 1039 reward responsiveness and, 1061 Triiodothyronine, 1127 Venlafaxine generalized anxiety disorder treated with, 858 selective serotonin reuptake inhibitors and, comparison between, 424 Voxel-based morphometry anomalous cerebral asymmetry in schizophrenia demonstrated with, 793 schizophrenia analyses, 465, 793 White matter diffusion tensor imaging of, in schizophrenia, 519 lesions, depression in elderly and, 663 wnt signaling genes schizophrenia and, 13 Working memory in schizophrenia catechol-O-methyltransferase genetic variation effects on, 72 diffusion tensor imaging of, 512 ZJ43, 86
www.sobp.org/journal
precuneus and, 332 rostral amygdala and, 858 amygdala-dependent fear learning modulated by, 821 depressed mood and, 391 vesicular glutamate transporter expression alterations in, in schizophrenia, 766 Anterior cingulotomy major depression treated with, 670 Anterior limb of interior capsule schizophrenia-related reductions in, 65 Antidepressants brain-derived neurotrophic factor and, 640, 642 ERK MAP kinase, 353 intracellular factors, 353 ketamine effects, 347, 348 methylphenidate-induced behavioral deficits normalized with, 309 neuropathic allodynia treated with, 633 Antipsychotic drugs astrocytes affected by, 759 oligodendrocytes affected by, 759 RGS4 variants effects on, for schizophrenia, 32 Anxiety/anxiety disorders in adolescents, functional magnetic resonance imaging of, 563 cocaine-induced, norepinephrine signaling through adrenergic receptors and, 1007 community versus clinical sampling, 884 family aggregation of, 884 serotonin transporter gene polymorphisms and, 840 Apolipoprotein E E4 allele, 609 Apomorphine gating-disruptive effects of, 748 Approach-related personality traits dopamine D4 receptor and, 197 Astrocytes, 759 Attachment infant, maternal love effects on, 415 Attentional engagement prefrontal inhibitory control deficits in schizophrenia associated with reductions in, 776 Attention-deficit/hyperactivity disorder blood lead levels and, 325 cingulate-precuneus interactions and, 332 emotional expressions in, misinterpreting of, 917 event-related potentials in, 784 methylphenidate for, 981 neurotrophic factors associated with genetic susceptibility to, 935 prolonged-release methylphenidate for, 981 Autism spectrum disorder affiliative behaviors and, 911 chromosomal abnormalities in, 1111 cognitive set in, 974 executive function in, 974 neural circuitry mediating shifts in behavioral response, 974 Behavior methylphenidate-induced deficits, antidepressants for normalization of, 309 self-injurious, 990 BIOL PSYCHIATRY 2008;63:1215–1221 © 2008 Society of Biological Psychiatry
1216 BIOL PSYCHIATRY 2008;63:1215–1221 Behavioral activation system dysregulation theory of bipolar disorder, 692 Biogenesis of lysosome-related organelles complex 1, 24 Bipolar disorder behavioral activation system dysregulation theory of, 692 biopsychosocial model of, 692 D-serine metabolism and, 997 left frontal cortical responses affected by, 692 mood symptoms in lamotrigine effects on, 125 pericentrin 2 expression in, 678 rapid cycling, 125 Brain cocaine responses, expectation effects on, 222 in schizophrenia loss of volume, 107 morphology, 475 structure patterns, 118 Brain rhythms, in schizophrenia, 728 Brain-derived neurotrophic factor antidepressant response and, 640, 642 in dentate gyrus, 642 hippocampal, 642 loss of, in dentate gyrus, 642 obsessive-compulsive disorder, 619 Bupropion nicotine patch and, for smoking cessation in schizophrenia, 1092 Cannabinoid-1 receptors, 1075 Catechol-O-methyltransferase working memory in schizophrenia affected by genetic variations in, 72 Caudate nucleus hyperactivity, in obsessive-compulsive disorder, 558 CB1 receptor, 1030 Cerebrum anomalous asymmetry of, in schizophrenia patients, 793 loss of volume, in schizophrenia, 107 Children alcohol use, 1039 depression in, 391 parental loss, effect on adult hypothalamic-pituitary-adrenal axis, 1147 tobacco use, 1039 CHRNA5/A3/B4 genes, 1039 Chromosomes, 7, 13, 594, 1047 abnormalities in, in autism spectrum disorder, 1111 15q25-26 linkage region, 1185 Cingulotomy, anterior major depression treated with, 670 Clozapine, 524 Cocaine anxiety induced by, norepinephrine signaling through adrenergic receptors and, 1007 expectation effects on brain responses to, 222 prenatal exposure to, 214, 1066 rewarding potency of, prenatal exposure effects on, 214 serotonin-6 receptors and, 207 Cocaine- and amphetamine-regulated transcript, 152 Cognitive control attention-deficit/hyperactivity disorder and, 325 Cognitive deficits in schizophrenia www.sobp.org/journal
Subject Index to Volume 63 ␣7 nicotinic receptor agonists for, 92 SSR180711 for, 92 Cognitive dysfunction psychotic disorders and, 602 Cognitive function magnetic seizure therapy and electroconvulsive shock effects on, 1163 Cognitive-behavioral therapy D-cycloserine enhancement of, for social anxiety, 544 Compulsivity orbitofrontal cortex damage and, 253 Conduct disorder in adolescents, 279 fear conditioning and affective modulation of startle reflex in, 279 Corticosteroids chronic use, amygdala volume in patients receiving, 704 Corticotropin-releasing factor alcoholism and, 137, 139 prepulse inhibition deficits mediated by, 360 raphe efferent activation to medial prefrontal cortex by, 832 CREB binding and activity of, 710 electroconsulvive seizures and, 710 Crhr1 alcoholism and, 139, 146 Cyclic adenosine monophosphate response element binding protein. See CREB Cytokines in schizophrenia, 801 D1, 1066 D-cycloserine cognitive-behavioral therapy for social anxiety enhanced using, 544 fear extinction and exposure therapy facilitated using, 1118 Decision making by stimulant users, 1054 Deep brain stimulation in obsessive-compulsive disorder, 542 Delta-opioid receptors, 633 Dentate gyrus brain-derived neurotrophic factor loss in, 642 pERK1/2 in, 353 Depression in children, 391 in elderly, white matter lesions as predictor of, 663 familial, 406 FKBP5 gene in, 1103 neurobiological markers of, 656 pharmacogenetic studies of, 1101 rostral anterior cingulate cortex volume and, in children, 391 selective serotonin reuptake inhibitor-resistant, 699 serotonin transporter gene polymorphisms and, 840, 847 white matter lesions and, in elderly, 663 Des-acyl ghrelin, 245 Dexamethasone/corticotropin-releasing factor test in men with major depression, 398 Diffusion tensor imaging of schizophrenia superior longitudinal fasciculus and working memory in, 512 white matter in, 519
Subject Index to Volume 63 Dizocilpine behaviors induced by, N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors for reduction of, 86 DKK4 schizophrenia and, 13 Dopamine D4 receptor approach-related personality traits and, 197 C-521T variant, 197 Dopamine D2 receptors in striatum, [18F]fallypride positron emission tomography evaluation of, 241 Dopaminergic agents prenatal cocaine exposure effects on, 214 Dorsal raphe nucleus, 1135 Dorsolateral prefrontal cortex imbalances in, in major depression, 369 Drug addiction brain norepinephrine and, 1005 orbitofrontal cortex and, 256 Drug-seeking behavior cocaine- and amphetamine-regulated transcript expression in, 152 hypothalamic neuropeptide systems and, 152 N-Acetylcysteine effects on, 338 orexin expression, 152 D-serine, 997 DTNBP1 methamphetamine psychosis associated with, 191 Dysbindin schizophrenia and, 24, 484 Elderly, depression in white matter lesions as predictor of, 663 Electroconsulvive seizures CREB and, 710 Electroconvulsive shock, 1163 Electroencephalographic alpha measures response to selective serotonin reuptake inhibitors predicted by, 1171 Emotion hippocampal lesions’ effect on, 1084 neural bases of regulation of, 577 Emotional expressions in attention-deficit/hyperactivity disorder, 917 Emotional interference processing in affective and cognitive-control brain circuitry in major depression, 377 Emotional judgment, 369 Emotional reactivity in adolescence, 927 Endocannabinoid system description of, 286 3,4-methylenedioxymethamphetamine response and, 1030 ERK MAP kinase, 353 Error processing by stimulant users, 1054 Event-related potentials in adolescents with schizophrenia, 785 in attention-deficit/hyperactivity disorder, 784 P3(00), 864 Executive function in autism, 974 Expectation, cocaine, 222
BIOL PSYCHIATRY 2008;63:1215–1221 1217 Extinction N-Acetylcysteine effects on, in cue- and heroin-induced drug seeking, 338 Face processing impairments in, in 22q11.2 deletion syndrome, 49 Familial depression, 406 Fear conditioning affective modulation of startle reflex and, in early-onset conduct disorder, 279 self-report fears and, genetic covariation between, 587 stress and, 819 Fear extinction and exposure therapy, 1118 Fear learning, amygdala-dependent, 821 Fetal alcohol exposure limbic-hypothalamic-pituitary-adrenal axis regulation affected by, 317 neonatal irritability and, 317 Fibroblast growth factors, 953 FKBP5, 1103 Fluoxetine, 1135 Fragile X syndrome, 963 Frontolimbic serotonin 2A receptor binding in affective disorder, 569 Frontotemporal lobe degeneration complex diseases, 946 Functional magnetic resonance imaging of adolescents with anxiety disorders, 563 face processing impairments in 22q11.2 deletion syndrome revealed with, 49 GABA transmission, 963 Gamma oscillations in neocortex, ketamine and MK-801 effects on, 730 in schizophrenia, 744 sensory-evoked, in chronic schizophrenia, 744 Gaze oxytocin effects on, 3 Generalized anxiety disorder riluzole for, hippocampal N-acetylaspartate concentration correlated with response to, 891 venlafaxine for, 858 Genome-wide association studies, 439 Glucocorticoid receptors, 360 Glutamate proton magnetic resonance spectroscopy measurement of, in premenstrual dysphoric disorder, 1178 release of in anterior cingulate cortex of schizophrenia patients, 766 ketamine effects on, 349 Gray matter loss in post-traumatic stress disorder, 550 in schizophrenia, 107 Heart rate, 1141 Heroin dependence hypothalamic-pituitary-adrenal axis response in, 172 metyrapone response in patients with, 172 N-acetylcysteine effects on seeking of, 338 Herpes simplex virus maternal exposure to, psychosis risks among offspring secondary to, 809 www.sobp.org/journal
1218 BIOL PSYCHIATRY 2008;63:1215–1221 Hippocampus in familial early onset major depressive disorder, 385 lesions in, emotional responses disrupted by, 1084 N-acetylaspartate concentration in, riluzole response for generalized anxiety disorder correlated with, 891 5-HT7 receptor phencyclidine-induced prepulse inhibition affected by inactivation of, 98 Human immunodeficiency virus, 899 Hypothalamic-pituitary-adrenal axis adult, childhood parental loss effects, 1147 childhood trauma effects on, 398, 1147 reactivity of, 847 regulation of, fetal alcohol exposure effects on, 317 stress-associated dysregulation of, 539 Impulse control nicotine seeking and, 301 Impulsivity nicotine seeking and, 301 orbitofrontal cortex damage and, 253 Infant maternal love effects on attachment behaviors in, 415 Inflammation, 1022 Inflammatory cytokines in schizophrenia, 801 Interior capsule anterior limb of, in schizophrenia, 65 Interneurons inhibitory cortical, deficiency in, 953 in neocortex, 650 -opioid receptor, 286 Ketamine antidepressant effects, 347, 349 glutamate release affected by, 349 locomotor sensitization to chronic use of, 178 wake-related aberrant ␥ oscillations in neocortex induced by, 730 Lamotrigine bipolar disorder-related mood symptoms treated with, 125 Lead exposure attention-deficit/hyperactivity disorder and, 325 Limbic system deactivation of, during acute psychosocial stress, 234 Linkage-disequilibrium mapping, 1185 Locomotor behavior sensitization of, to chronic ketamine use, 178 Loss-chasing, 293 Magnetic seizure therapy, 1163 Major depression amygdala volumes in, 385 anterior cingulotomy for, 670 chromosome 15q25-26 linkage region, 1185 dexamethasone/corticotropin-releasing factor test in, 398 dorsolateral prefrontal cortex imbalances in, 369 emotional interference processing alterations in, 377 familial, 385 hippocampal volumes in, 385 incentives in, 686 memory sensitivity for negative stimuli in, 1155 www.sobp.org/journal
Subject Index to Volume 63 monetary incentives in, neural responses to, 686 negativity bias in, 377 neuroticism and, 569 triiodothyronine augmentation in, brain bioenergetics and response to, 1127 Maternal love functional neuroanatomy of, 415 MDMA. See 3,4-Methylenedioxymethamphetamine Medical research, 725 MEGF10, 441 Memory sensitivity for negative stimuli in major depression, 1155 subjective, 609 Metabotropic glutamate receptors N-acetylaspartylglutamate peptidase inhibition via, for phencyclidine and dizocilpine induced behaviors, 86 Methamphetamine anterior cingulate cortex affected by, 184 psychosis induced by, DTNBP1 associated with, 191 response inhibition impairments caused by, 184 Methylation of reelin promoter region in schizophrenia, 530 3,4-Methylenedioxymethamphetamine, 1030 Methylenetetrahydrofolate reductase polymorphisms negative symptoms in schizophrenia correlated with, 42 ␣-Methyl-para-tyrosine, 241 Methylphenidate behavioral deficits induced by, antidepressant treatment effects, 309 emotional expressions in attention-deficit/hyperactivity disorder affected by, 917 prolonged-release, 981 Metyrapone mood and neuroendocrine response to, in heroindependent patients, 172 Mismatch negativity in schizophrenia, 58 MK-801 wake-related aberrant ␥ oscillations in neocortex induced by, 730 Monetary incentives in major depression, 686 Monoamine oxidase inhibitors nicotine withdrawal-induced place aversion prolonged by, 159 Motor cortex repetitive transcranial magnetic stimulation-induced inhibition of, 231 N-acetylaspartate, 891 N-acetylaspartylglutamate peptidase inhibition phencyclidine and dizocilpine induced behaviors reduced by, 86 N-Acetylcysteine heroin-induced drug seeking reduced by, 338 Natural killer cells, 899 Negative emotion, 577 Negative emotional judgment, 369 Neocortex interneurons in, 650 ketamine and MK-801 inducement of wake-related aberrant ␥ oscillations in, 730 Neuregulin 1 gene missense mutations on, 17 schizophrenia and, 17
Subject Index to Volume 63 Neurokinin 1 receptor territorial aggression and, 271 Neuronal oscillation, 1075 Neuropathic allodynia, 633 Neuroticism human-mouse quantitative trait locus concordance and, 874 major depression and, 569 Neurotrophic factors genetic susceptibility to attention-deficit/hyperactivity disorder and, 935 Nicotine. See also Tobacco smoking craving, 164 impulse control and, 301 impulsivity and, 301 non-drug-related rewards and, 1061 withdrawal-induced place aversion, monoamine oxidase inhibition effects on, 159 Nicotine patch bupropion and, for smoking cessation in schizophrenia, 1092 ␣7 Nicotinic receptor agonists cognitive deficits in schizophrenia treated with, 92 NMDA schizophrenia and, 9 NMDA antagonists ketamine. See Ketamine MK-801, 730 wake-related aberrant ␥ oscillations in neocortex induced by, 730 Norepinephrine drug addiction and, 1005 signaling through -adrenergic receptors, cocaine-induced anxiety secondary to, 1007 NTRK2, 619 NTRK3, 1185 Nucleus accumbens gene expression in, 748 serotonin-6 receptor expression in, effects on cocaine addiction, 207 signaling pathways, 748 Obestatin, 245 Obsessive-compulsive disorder BDNF/NTRK2 signaling pathway in genetic susceptibility to, 619 caudate nucleus hyperactivity in, 558 deep brain stimulation in, 542 neuronal single-unit recordings in, 542 obsessions in, 558 Olanzapine, 524 Oligodendrocytes, 759 Opiate dependence, 1013 Orbitofrontal cortex damage to, impulsivity and compulsivity and, 253 drug addiction and, 256 Orexin drug-seeking behavior and, 152 Oxytocin gaze affected by, 3 peer recognition and, 3 P3(00) event-related potential, 864 Panic disorder
BIOL PSYCHIATRY 2008;63:1215–1221 1219 chromosome 13 and, 594 Pathological gambling loss-chasing in, 293 Pergolide repetitive transcranial magnetic stimulation potentiated by, 231 Pericentrin 2 expression of, in bipolar disorder, 678 Peripheral inflammation, 1022 pERK1/2, 353 Phencyclidine behaviors induced by, N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors for reduction of, 86 cognitive deficits induced by, SSR180711 for, 92 prepulse inhibition disruption induced by, 5-HT7 receptor inactivation effects on, 98 Phenomics, 439 PICK1, 997 Place aversion, nicotine withdrawal-induced, 159 Positron emission tomography [18F], 241 limbic system deactivation during acute psychosocial stress evaluated using, 234 Post-traumatic stress disorder anterior cingulate gray matter loss in, 550 cortical reduction from, 539 prazosin effects on nighttime symptoms in, 629 twin study of, 539 Prazosin, 629 Precuneus anterior cingulate cortex and, in attention-deficit/ hyperactivity disorder, 332 Prefrontal cortex dorsolateral, imbalances in major depression, 369 medial, raphe efferent activation by corticotropin-releasing factor, 832 in nonpsychotic siblings of schizophrenia individuals, 490 right prefrontal cortical folding in adolescents at risk for schizophrenia, 80 Pregnancy herpes simplex virus exposure, psychosis risks among offspring secondary to, 809 Premenstrual dysphoric disorder, 1178 Prenatal period cocaine exposure during, 214, 1066 Prepulse inhibition apomorphine sensitivity, 748 CRF1 mediation of deficits in, 360 neuregulin 1 gene missense mutations effect on, 17 phencyclidine-induced, 5-HT7 receptor inactivation effects on, 98 Progranulin gene, 946 Prolactin, 909 Proton magnetic resonance spectroscopy of glutamate levels in premenstrual dysphoric disorder, 1178 Psychomotor slowing, 1022 Psychosis maternal exposure to herpes simplex virus associated with psychosis in offspring, 809 methamphetamine-related, DTNBP1 associated with, 191 Psychosocial stress limbic system deactivation during, 234 www.sobp.org/journal
1220 BIOL PSYCHIATRY 2008;63:1215–1221 Psychotic disorders cognitive dysfunction and, 602 Quantitative trait locus human-mouse concordance, 874 for P3 amplitude, 864 22q11.2 deletion syndrome face processing impairments in, 49 Raphe efferents, 832 Raphe nucleus, 1135 Recognition memory, delayed in schizophrenia, 498 Reelin promoter region in schizophrenia, 530 Relocation stress, 990 Repetitive transcranial magnetic stimulation dopaminergic potentiation of motor cortex inhibition induced by, 231 Response inhibition methamphetamine effects on, 184 RGS4 schizophrenia response to antipsychotic treatment affected by, 32 Ribonucleic acid, 946 Right prefrontal cortical folding in adolescents at risk for schizophrenia, 80 Riluzole, 891 Rostral anterior cingulate cortex amygdala-dependent fear learning modulated by, 821 depression in children correlated with volume of, 391 Sad facial processing, 656 Salvinorin A, 286 Sarcosine, 9 Schizophrenia adolescents clozapine and olanzapine for, 524 event-related potentials in, 784 right prefrontal cortical folding in at-risk adolescents, 80 AKT1 and, 449 anterior cingulate cortex, 766 antipsychotic treatment for RGS4 variants associated with response to, 32 biogenesis of lysosome-related organelles complex 1 protein involvement in, 24 brain rhythms in, 728 brain structure patterns in, 118 brain volume in, 107, 475 bupropion and nicotine patch for smoking cessation in, 1092 cannabinoid-1 receptors effects on sensory gating and neuronal oscillation, 1075 cognitive deficits in, ␣7 nicotinic receptor agonists for, 92 cytokine alterations in, 801 delayed recognition memory in, 498 DKK4 and, 13 D-serine metabolism and, 997 dysbindin and, 24, 484 early-onset clozapine for, 524 mismatch negativity patterns in, 58 www.sobp.org/journal
Subject Index to Volume 63 olanzapine for, 524 white matter in, 519 endophenotype, 458, 498 first-degree relatives of patients with, striatal dopamine synthesis in, 114 forward model circuitry dysfunction in, 736 functional deficits in, 505 gamma oscillations in, sensory-evoked, 744 gray matter volume and, 465 inflammatory cytokine alterations in, 801 interior capsule anterior limb in, 65 late, mismatch negativity patterns in, 58 MEGF10 and, 441 methylenetetrahydrofolate reductase polymorphisms and, 42 mismatch negativity reduction patterns in, 58 motor-sensory communication dysfunction in, 736 negative symptoms in, 42, 86 neuregulin 1 gene and, 17 neuropsychological deficits in, 505 NMDA and, 9 nonverbal delayed recognition in, 498 phenotypes for, 458, 465 predictors of, 80 prefrontal cortex function in, 490 prefrontal inhibitory control deficits in, attentional engagement effects on, 776 progressive brain volume loss in, 107 reelin promoter region in, methylation status of, 530 sarcosine for, 9 smoking cessation in, 1092 striatal dopamine synthesis in first-degree relatives of patients with, 114 superior longitudinal fasciculus in, 512 vesicular glutamate transporter expression alterations in, 766 visual processing deficits in, 484 voxel-based morphometry analyses in, 465, 793 white matter in, 519 wnt signaling genes in, 13 working memory in catechol-O-methyltransferase genetic variation effects on, 72 diffusion tensor imaging of, 512 Seizures, electroconsulvive CREB and, 710 Selective serotonin reuptake inhibitors depression resistant to, 699 electroencephalographic alpha measures predict therapeutic response to, 1171 natural killer cell innate immunity affected by, 899 venlafaxine and, comparison between, 424 Self-injurious behavior, 990 Sensory gating, 1075 Serotonin 2A receptor binding in affective disorder, 569 Serotonin 1A receptors, 1135 Serotonin-6 receptors cocaine addiction and, 207 Serotonin transporter gene polymorphisms amygdala activation and, 852 anxiety disorders and, 840 depression and, 840, 847
BIOL PSYCHIATRY 2008;63:1215–1221 1221
Subject Index to Volume 63 limbic-hypothalamic-pituitary-adrenal axis regulation and, 317 neonatal irritability and, 317 stress and, 847 Smoking. See also Nicotine bupropion and nicotine patch for cessation of, in schizophrenia, 1092 CHRNA5/A3/B4 genes and, 1039 reward responsiveness and, 1061 Social aggression testosterone effects, 263 Social anxiety chromosome 13 and, 594 D-cycloserine enhancement of exposure therapy for, 544 SSR180711, 92 Startle reflex affective modulation of, in early-onset conduct disorder, 279 Stimulants behavioral and neural activation responses to error rates during decision making in users of, 1054 Stress fear conditioning and, 819 low heart rate as marker of resilience to, 1141 nicotine craving induced by, 164 psychosocial, limbic system deactivation during, 234 sensitivity to, 164 serotonin transporter gene and, 847 Striatum D1 signaling in, 1066 dopamine synthesis, in first-degree relatives of schizophrenia patients, 114 GABA transmission, in mouse model for fragile X syndrome, 963 immediate-early gene induction in, after prenatal cocaine exposure, 1066
Subjective memory complaints, 609 Substantia nigra, 1022 Superior longitudinal fasciculus in schizophrenia, 512 Territorial aggression neurokinin 1 receptor blockade and, 271 Terrorism, 725 Testosterone social aggression and, 263 Tobacco smoking. See also Nicotine bupropion and nicotine patch for cessation of, in schizophrenia, 1092 CHRNA5/A3/B4 genes and, 1039 reward responsiveness and, 1061 Triiodothyronine, 1127 Venlafaxine generalized anxiety disorder treated with, 858 selective serotonin reuptake inhibitors and, comparison between, 424 Voxel-based morphometry anomalous cerebral asymmetry in schizophrenia demonstrated with, 793 schizophrenia analyses, 465, 793 White matter diffusion tensor imaging of, in schizophrenia, 519 lesions, depression in elderly and, 663 wnt signaling genes schizophrenia and, 13 Working memory in schizophrenia catechol-O-methyltransferase genetic variation effects on, 72 diffusion tensor imaging of, 512 ZJ43, 86
www.sobp.org/journal